What the company actually pays, and whether its own cash supports it.
Dividends view
Yield
3.79%Above 5Y avg (3.15%)
Annual Rate
CNY 0.53Paid semi-annual
Payout Ratio
137.4%High
Payback Period
26.7 yr
Last Ex-Dividend
Oct 15, 2026
The reported statements, read against the company's own industry.
Financials view
Market Capitalization
8.08BCNY
1.21B · vs all stocks (USD)
Updated Nov 22, 2026
Trailing P/E
74.00x
vs Medical Instruments & Supplies peers
Updated Nov 22, 2026
Revenue (TTM)
1.65BCNY
247.28M · vs all stocks (USD)
Updated Nov 22, 2026
Profit Margin
6.77%
vs Medical Instruments & Supplies peers
Updated Nov 22, 2026
Beta
0.4910x
vs all stocks
Updated Nov 22, 2026
52-Week Change
-29.45%
vs all stocks
Updated Nov 22, 2026
Forward Annual Dividend Yield
3.79%
vs all stocks
Updated Nov 22, 2026
Market Capitalization
8.08BCNY
1.21B · vs all stocks (USD)
Updated Nov 22, 2026
Enterprise Value
5.97BCNY
894.22M · vs all stocks (USD)
Updated Nov 22, 2026
Trailing P/E
74.00x
vs Medical Instruments & Supplies peers
Updated Nov 22, 2026
Forward P/E
17.80x
vs Medical Instruments & Supplies peers
Updated Nov 22, 2026
Price to Sales (TTM)
4.90x
vs Medical Instruments & Supplies peers
Updated Nov 22, 2026
Price to Book (MRQ)
1.15x
vs Medical Instruments & Supplies peers
Updated Nov 22, 2026
Enterprise to Revenue
3.62x
vs Medical Instruments & Supplies peers
Updated Nov 22, 2026
Enterprise to EBITDA
20.39x
vs Medical Instruments & Supplies peers
Provider-reported. Enterprise Value ÷ EBITDA (TTM) on this page gives 13.98×.Updated Nov 22, 2026
Gross Margin
69.13%
vs Medical Instruments & Supplies peers
Updated Nov 22, 2026
Profit Margin
6.77%
vs Medical Instruments & Supplies peers
Updated Nov 22, 2026
Operating Margin
2.82%
vs Medical Instruments & Supplies peers
Updated Nov 22, 2026
Return on Assets (TTM)
0.30%
vs Medical Instruments & Supplies peers
Updated Nov 22, 2026
Return on Equity (TTM)
0.97%
vs Medical Instruments & Supplies peers
Updated Nov 22, 2026
Revenue (TTM)
1.65BCNY
247.28M · vs all stocks (USD)
Updated Nov 22, 2026
Revenue per Share (TTM)
2.83CNYUpdated Nov 22, 2026
Quarterly Revenue Growth
11.30%
vs Medical Instruments & Supplies peers
Updated Nov 22, 2026
Gross Profit (TTM)
1.17BCNY
175.44M · vs all stocks (USD)
Updated Nov 22, 2026
EBITDA (TTM)
426.81MCNY
63.97M · vs all stocks (USD)
Updated Nov 22, 2026
Net Income (TTM)
111.66MCNY
16.74M · vs all stocks (USD)
Updated Nov 22, 2026
Quarterly Earnings Growth (YoY)
-78.90%
vs Medical Instruments & Supplies peers
Updated Nov 22, 2026
Operating Cash Flow (TTM)
239.40MCNY
35.88M · vs all stocks (USD)
Updated Nov 22, 2026
Levered Free Cash Flow (TTM)
-263.25MCNY
-39.46M · vs all stocks (USD)
Updated Nov 22, 2026
Forward Annual Dividend Rate
0.5300CNYUpdated Nov 22, 2026
Forward Annual Dividend Yield
3.79%
vs all stocks
Updated Nov 22, 2026
Trailing Annual Dividend Rate
0.5260CNYUpdated Nov 22, 2026
Trailing Annual Dividend Yield
3.76%
vs all stocks
Updated Nov 22, 2026
5-Year Average Dividend Yield
3.15%
vs all stocks
Updated Nov 22, 2026
Payout Ratio
137.37%
vs Medical Instruments & Supplies peers
Provider-reported. Trailing Annual Dividend Rate ÷ Diluted EPS (TTM) on this page gives 276.84%.Updated Nov 22, 2026
Minority Interest (Equity)
73.98MCNYFY2025 · Dec 31, 2025
Revenue
1.64BCNYFY2025 · Dec 31, 2025
Cost of Goods Sold
397.48MCNYFY2025 · Dec 31, 2025
Gross Profit
1.24BCNYFY2025 · Dec 31, 2025
Operating Income
210.49MCNY
31.55M · vs all stocks (USD)
FY2025 · Dec 31, 2025
Pre-tax Income
175.08MCNYFY2025 · Dec 31, 2025
Income Tax Expense
21.16MCNYFY2025 · Dec 31, 2025
Net Income
153.92MCNYFY2025 · Dec 31, 2025
EBIT
199.21MCNYFY2025 · Dec 31, 2025
EBITDA (Income Statement)
426.81MCNYFY2025 · Dec 31, 2025
Research & Development
229.11MCNYFY2025 · Dec 31, 2025
Selling, General & Administrative
377.97MCNYFY2025 · Dec 31, 2025
Other Operating Expenses
19.70MCNYFY2025 · Dec 31, 2025
Non-operating Interest Income
86.82MCNYFY2025 · Dec 31, 2025
Non-operating Interest Expense
24.13MCNYFY2025 · Dec 31, 2025
EPS (Basic)
0.3400CNYFY2025 · Dec 31, 2025
EPS (Diluted)
0.3400CNYFY2025 · Dec 31, 2025
Basic Shares Outstanding
585.11MSharesFY2025 · Dec 31, 2025
Diluted Shares Outstanding
585.11MSharesFY2025 · Dec 31, 2025
Net Income from Continuing Operations
153.92MCNYFY2025 · Dec 31, 2025
Minority Interests (P&L)
45.01MCNYFY2025 · Dec 31, 2025
Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025
Operating Cash Flow
137.88MCNYFY2025 · Dec 31, 2025
Free Cash Flow
-229.44MCNYFY2025 · Dec 31, 2025
Cash & Cash Equivalents (End of Period)
3.75BCNYFY2025 · Dec 31, 2025
Starting Profit (CF Statement)
153.92MCNYFY2025 · Dec 31, 2025
Other Non-cash Items
43.56MCNYFY2025 · Dec 31, 2025
Change in Accounts Receivable (CF)
-39.97MCNYFY2025 · Dec 31, 2025
Change in Other Assets/Liabilities
-19.64MCNYFY2025 · Dec 31, 2025
Capital Expenditures
-367.32MCNYFY2025 · Dec 31, 2025
Net Acquisitions
-715.47MCNYFY2025 · Dec 31, 2025
Purchase of Investments
-1.05BCNYFY2025 · Dec 31, 2025
Sale of Investments
847.50MCNYFY2025 · Dec 31, 2025
Net Investing Cash Flow
-1.29BCNYFY2025 · Dec 31, 2025
Long-term Debt Issuance
1.11BCNYFY2025 · Dec 31, 2025
Long-term Debt Payments
-403.13MCNYFY2025 · Dec 31, 2025
Common Dividends Paid
-333.68MCNYFY2025 · Dec 31, 2025
Other Financing Charges
4.58MCNYFY2025 · Dec 31, 2025
Net Financing Cash Flow
374.38MCNYFY2025 · Dec 31, 2025
Shares Outstanding
579.39MSharesUpdated Nov 22, 2026
Float Shares
295.70MSharesUpdated Nov 22, 2026
% Held by Insiders
47.42%
vs all stocks
Updated Nov 22, 2026
% Held by Institutions
5.97%
vs all stocks
Updated Nov 22, 2026
Total Cash (MRQ)
3.62BCNY
543.20M · vs all stocks (USD)
Updated Nov 22, 2026
Total Cash per Share (MRQ)
6.38CNYUpdated Nov 22, 2026
Total Debt (MRQ)
1.51BCNY
225.67M · vs all stocks (USD)
Updated Nov 22, 2026
Total Debt to Equity (MRQ)
0.2132x
vs Medical Instruments & Supplies peers
Updated Nov 22, 2026
Current Ratio (MRQ)
4.54x
vs Medical Instruments & Supplies peers
Updated Nov 22, 2026
Book Value per Share (MRQ)
12.26CNYUpdated Nov 22, 2026
Total Assets
9.53BCNY
1.43B · vs all stocks (USD)
FY2025 · Dec 31, 2025
Total Current Assets
5.27BCNYFY2025 · Dec 31, 2025
Total Liabilities
2.34BCNYFY2025 · Dec 31, 2025
Total Non-current Assets
4.25BCNYFY2025 · Dec 31, 2025
Total Non-current Liabilities
1.13BCNYFY2025 · Dec 31, 2025
Total Current Liabilities
1.21BCNYFY2025 · Dec 31, 2025
Cash
3.84BCNYFY2025 · Dec 31, 2025
Cash Equivalents
125.17MCNYFY2025 · Dec 31, 2025
Cash & Cash Equivalents
3.97BCNYFY2025 · Dec 31, 2025
Other Short-term Investments
157.10MCNYFY2025 · Dec 31, 2025
Accounts Receivable
621.44MCNYFY2025 · Dec 31, 2025
Inventory
413.69MCNYFY2025 · Dec 31, 2025
Accounts Payable
364.79MCNYFY2025 · Dec 31, 2025
Short-term Debt
148.85MCNYFY2025 · Dec 31, 2025
Other Current Liabilities
2.31MCNYFY2025 · Dec 31, 2025
Long-term Debt
978.47MCNYFY2025 · Dec 31, 2025
Common Stock (Book)
579.39MCNYFY2025 · Dec 31, 2025
Retained Earnings
4.79BCNYFY2025 · Dec 31, 2025
Total Shareholders' Equity
7.19BCNY
1.08B · vs all stocks (USD)
FY2025 · Dec 31, 2025
Treasury Stock
143.23MCNYFY2025 · Dec 31, 2025
52-Week Low
13.40CNYUpdated Nov 22, 2026
52-Week High
22.80CNYUpdated Nov 22, 2026
52-Week Change
-29.45%
vs all stocks
Updated Nov 22, 2026
Beta
0.4910x
vs all stocks
Updated Nov 22, 2026
50-Day MA
15.89CNYUpdated Nov 22, 2026
200-Day MA
16.53CNYUpdated Nov 22, 2026
Avg 10-Day Volume
2.86MSharesUpdated Nov 22, 2026
Avg 30-Day Volume
3.18MSharesUpdated Nov 22, 2026
Diluted EPS (TTM)
0.1900CNYUpdated Nov 22, 2026
1 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Cash Elevated Relative to Current Liabilities and Total Assets
Its cash covers more of its near-term bills than in its industry, and is a large share of everything it owns.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
High gross margins eroded by operating costsNotable
Gross Margin: 0.69Profit Margin: 0.07
Financial Health
Altman Z-Score 3.81: safe zoneNotable
Altman Z-Score: 3.81
Supply Chain
Upstream position: supplies 5 industries, depends on 1Notable
Outgoing: 5.00Incoming: 1.00
Scale
Market cap is $1.21B, above the global median of $1.14BNotable
Market cap (USD): 1,211,654,629.792Global Median: 1,137,180,293.291
Companies that share the same coordination system — how they create, deliver, or capture value.